药物评估：阿地妥单抗，一种工程化人源抗上皮细胞黏附分子抗体。
Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.
作者信息
Kirman Irena, Whelan Richard L
机构信息
Columbia University, 630 VWest 168th Street, New York, NY 10032, USA.
出版信息
Curr Opin Mol Ther. 2007 Apr;9(2):190-6.
PMID:17458174
Abstract
Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas, including breast and prostate cancer. Adecatunmumab is a fully human antibody targeting epithelial cell adhesion molecule (EpCAM). Adecatumumab is currently undergoing phase II clinical trials in breast and prostate cancer.
摘要
微美公司（Micromet Inc）与默克雪兰诺公司（Merck Serono SA）合作，正在研发阿地卡妥单抗，用于潜在治疗包括乳腺癌和前列腺癌在内的腺癌。阿地卡妥单抗是一种靶向上皮细胞粘附分子（EpCAM）的全人源抗体。阿地卡妥单抗目前正在进行乳腺癌和前列腺癌的II期临床试验。
Zotero 插件